PREOPERATIVE DENOSUMAB AND FEASIBILITY OF LESS MORBID SURGERY IN CAMPANACCI STAGE 3 GIANT CELL TUMOUR OF BONE. | ScholarDeck

Paper

PREOPERATIVE DENOSUMAB AND FEASIBILITY OF LESS MORBID SURGERY IN CAMPANACCI STAGE 3 GIANT CELL TUMOUR OF BONE.

New research · Orthopedics

Journal of Ayub Medical College, Abbottabad : JAMC · 3w

StudyJournal of Ayub Medical College, Abbottabad : JAMC· 2024

PREOPERATIVE DENOSUMAB AND FEASIBILITY OF LESS MORBID SURGERY IN CAMPANACCI STAGE 3 GIANT CELL TUMOUR OF BONE.

Muhammad Asif Rasheed, Muhammad Suhail Amin, Muhammad Sohaib Nadeem … Areej Fatima

Read paper

OrthopedicsStudyTreatment

After denosumab, intralesional curettage became feasible in 78.3% of cases.

PREOPERATIVE DENOSUMAB AND FEASIBILITY OF LESS MORBID SURGERY IN CAMPANACCI STAGE 3 GIANT CELL TUMOUR OF BONE.

Muhammad Asif Rasheed … Areej Fatima

Journal of Ayub Medical College, Abbottabad · 2024

Background

Giant cell tumour of bone (giant cell tumour of bone) is a rare, locally aggressive benign bone tumour with slight female sex predilection and affecting young adults 20-40 years of age.

Methods

Were recruited by purposive sampling technique as per inclusion/exclusion criteria.

n = 23 patients

Results

curettage, the less invasive option, became doable in most patients

56.5%

Pre-denosumab (resecti

78.3%

Post-denosumab (intral

More results

Total of 23 patients were a part of this study.

Mean pain scores and MSTS scores prior to and after denosumab were statistically significant with p-value <0.01.

Pre-denusomab, there was inclination towards resection arthroplasty as the treatment procedure (56.5%).

“

Conclusion

Denosumab has potential role for giant cell tumour of bone, it makes a less morbid surgery technically feasible. However, recurrence needs to be probed in long term follow up studies.

Read paper